Mylan’s EpiPen tornado is far from its first storm of controversy. The top brass has caught fire for personal use of company aircraft, an unearned degree, outsized compensation and alleged conflicts of interest.
EpiPen has buzz. Unfortunately for Mylan, the buzz isn’t good. FiercePharma has been tracking the story for months: Price hikes, marketing tactics, executive pay, they're all here in a trending roundup.